Shares of Amprius Technologies jumped 10.1% to $10.73 Monday morning after the company disclosed a U.S. Department of War grant of up to $75 million to build a domestic drone-battery production line — a deal that validates its defense ambitions but comes loaded with conditions investors should parse carefully.
• Washington Is Paying Most of the Tab, but the Check Hasn't Cleared
The total conversion project is expected to cost approximately $100 million, including in-kind investments from Amprius and its South Korean manufacturing partner.
The grant was awarded through the DoW's Industrial Base Analysis and Sustainment program, which funds domestic manufacturing capabilities critical to national defense. That means Washington could cover roughly three-quarters of the bill — if the money actually flows. The 12 million cells a year expected by early 2028 is proposed manufacturing capacity rather than booked deliveries. No customer orders are attached, and future payments hinge on milestone approvals and congressional appropriations.
• Defense Demand Is Real, and Amprius Already Has Paying Customers
Three Amprius customers received major contract awards in a single quarter — Kraus Hamdani Aerospace secured a separate $270 million Air Force contract, AeroVironment received a $117 million Army agreement, and Teledyne FLIR landed a European nano-drone order. All three platforms run on Amprius cells.
The company's silicon anode cells deliver twice the flight time of standard lithium-ion. That performance edge is what makes the grant strategically meaningful: it cements Amprius as the supplier Washington is betting on for legally compliant drone power.
• Revenue Is Surging, but Profits Remain Elusive
Amprius raised its 2026 revenue outlook to at least $140.0 million, reiterating targets for net loss below $10.0 million, and positive adjusted EBITDA of at least $4 million.
Q2 2026 revenue was $34.0 million, up 126% year-over-year. Growth is impressive, yet over the trailing twelve months the company posted $109 million in revenue and $38.4 million in losses.
Amprius holds $74.5 million in cash against just $6.4 million in debt — comfortable for now, but the grant's milestone structure means it won't fill coffers overnight.
• The Market Is Pricing Hope, Not Certainty
Amprius carries a market cap of roughly $1.44 billion — over 10× its guided 2026 revenue — while short interest sits at 15.16% of shares outstanding , a sign skeptics remain vocal. A beta of 2.34 means the stock swings far more than the broader market. Today's pop rewards believers, but the grant's conditional nature means the real test comes when Amprius must hit production milestones — and fill those 12 million cell slots with actual orders.